C10-substituted camptothecin analogs
    3.
    发明授权
    C10-substituted camptothecin analogs 有权
    C10取代的喜树碱类似物

    公开(公告)号:US07687497B2

    公开(公告)日:2010-03-30

    申请号:US11974756

    申请日:2007-10-16

    摘要: The novel C10-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW

    摘要翻译: 本发明的新颖的C10修饰的喜树碱类似物及其药学上可接受的盐:(i)具有有效的抗肿瘤活性(即纳米摩尔或亚纳摩尔浓度),用于在体外抑制人和动物肿瘤细胞的生长; (ii)是拓扑异构酶I的有效抑制; (iii)对MDR / MRP耐药性不敏感; (iv)不需要代谢药物活化:(v)缺乏A环或B环的葡糖醛酸化; (vi)降低与血浆蛋白质的药物结合亲和力; (vii)维持内酯稳定性; (viii)维持药物效力; 和(ix)具有低分子量(例如MW <600)。

    C7-substituted camptothecin analogs
    4.
    发明授权
    C7-substituted camptothecin analogs 有权
    C7取代的喜树碱类似物

    公开(公告)号:US07687496B2

    公开(公告)日:2010-03-30

    申请号:US11974754

    申请日:2007-10-16

    CPC分类号: C07F7/0812 A61K31/4375

    摘要: The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW

    摘要翻译: 本发明的新颖的C7-改性的喜树碱类似物及其药学上可接受的盐:(i)在体外具有抑制人和动物肿瘤细胞生长的有效的抗肿瘤活性(即纳摩尔或亚纳摩尔浓度) (ii)是拓扑异构酶I的有效抑制; (iii)对MDR / MRP耐药性不敏感; (iv)不需要代谢药物活化:(v)缺乏A环或B环的葡糖醛酸化; (vi)降低与血浆蛋白质的药物结合亲和力; (vii)维持内酯稳定性; (viii)维持药物效力; 和(ix)具有低分子量(例如MW <600)。

    C10-substituted camptothecin analogs
    5.
    发明申请
    C10-substituted camptothecin analogs 有权
    C10取代的喜树碱类似物

    公开(公告)号:US20090099166A1

    公开(公告)日:2009-04-16

    申请号:US11974756

    申请日:2007-10-16

    摘要: The novel C10-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW

    摘要翻译: 本发明的新颖的C10修饰的喜树碱类似物及其药学上可接受的盐:(i)具有有效的抗肿瘤活性(即纳米摩尔或亚纳摩尔浓度),用于在体外抑制人和动物肿瘤细胞的生长; (ii)是拓扑异构酶I的有效抑制; (iii)对MDR / MRP耐药性不敏感; (iv)不需要代谢药物活化:(v)缺乏A环或B环的葡糖醛酸化; (vi)降低与血浆蛋白质的药物结合亲和力; (vii)维持内酯稳定性; (viii)维持药物效力; 和(ix)具有低分子量(例如MW <600)。

    C7- substituted camptothecin analogs
    6.
    发明申请
    C7- substituted camptothecin analogs 有权
    C7-取代的喜树碱类似物

    公开(公告)号:US20090099224A1

    公开(公告)日:2009-04-16

    申请号:US11974754

    申请日:2007-10-16

    CPC分类号: C07F7/0812 A61K31/4375

    摘要: The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW

    摘要翻译: 本发明的新颖的C7-改性的喜树碱类似物及其药学上可接受的盐:(i)具有用于在体外抑制人和动物肿瘤细胞生长的有效抗肿瘤活性(即纳摩尔或亚纳摩尔浓度) (ii)是拓扑异构酶I的有效抑制; (iii)对MDR / MRP耐药性不敏感; (iv)不需要代谢药物活化:(v)缺乏A环或B环的葡糖醛酸化; (vi)降低与血浆蛋白质的药物结合亲和力; (vii)维持内酯稳定性; (viii)维持药物效力; 和(ix)具有低分子量(例如MW <600)。

    Process for making camptothecin derivatives
    7.
    发明授权
    Process for making camptothecin derivatives 有权
    制造喜树碱衍生物的方法

    公开(公告)号:US06723849B1

    公开(公告)日:2004-04-20

    申请号:US10627444

    申请日:2003-07-25

    IPC分类号: C07D49122

    CPC分类号: C07D491/22

    摘要: A process for synthesizing highly lipophilic derivatives of camptothecin. The process includes reacting dissolved, underivatized camptothecin with an aldehyde in a modified Minisci-type alkylation reaction to produce 7-substituted derivatives of camptothecin.

    摘要翻译: 合成喜树碱高亲脂性衍生物的方法。 该方法包括使改性Minisci型烷基化反应中的溶解的,未衍生的喜树碱与醛反应以产生喜树碱的7-取代的衍生物。

    Process for making camptothecin derivatives
    10.
    发明授权
    Process for making camptothecin derivatives 失效
    制造喜树碱衍生物的方法

    公开(公告)号:US07030243B1

    公开(公告)日:2006-04-18

    申请号:US10976109

    申请日:2004-10-28

    IPC分类号: C07D491/22

    CPC分类号: C07D491/22

    摘要: A process for synthesizing highly lipophilic derivatives of camptothecin. The process includes reacting dissolved, underivatized camptothecin with a silylated heterocyclic compound in a modified Minisci-type alkylation reaction to produce 7-substituted derivatives of camptothecin.

    摘要翻译: 合成喜树碱高亲脂性衍生物的方法。 该方法包括在经修饰的Minisci型烷基化反应中使溶解的,未衍生的喜树碱与甲硅烷基化杂环化合物反应,以产生喜树碱的7-取代衍生物。